On May 15, 2026, Cocrystal Pharma, Inc. (COCP) announced financial results for the first quarter of 2026 ending March 31, 2026 and provided a business update. The company recently presented on the mechanism of action and clinical advancement of CDI-988 at the 39th International Conference on Antiviral Research (ICAR 2026). The company is currently conducting a Phase 1b human challenge study with CDI-988. In the first stage, healthy volunteers are being challenged with norovirus GII.2 (Snow Mountain Virus) challenge inoculum. This will be followed up by prevention and treatment cohorts, with the primary endpoint being the reduction in the incidence of clinical symptoms and secondary endpoints including reduction in viral shedding, disease severity, safety, and pharmacokinetics.
